Certificate of Analysis

Recombinant RNasin® Ribonuclease Inhibitor:

Part# 9PIN251
Revised 4/18

Part No.	Size (units)
N2511	2,500
N2515	10,000

Enzyme Storage Buffer: Recombinant RNasin® Ribonuclease Inhibitor is supplied in 20mM HEPES-KOH (pH 7.6), 50mM KCl, 8mM DTT, 50% (v/v) glycerol.

Storage Conditions: See the Product Information Label for storage recommendations. Avoid multiple freeze-thaw cycles and exposure to frequent temperature changes. See the expiration date on the Product Information Label.

Source: *E. coli* cells expressing a recombinant clone.

Unit Definition: One unit is defined as the amount of Recombinant RNasin® Ribonuclease Inhibitor required to inhibit the activity of 5ng of ribonuclease A by 50%. Activity is measured by the inhibition of hydrolysis of cytidine 2´,3´-cyclic monophosphate by ribonuclease A. The unit concentration is listed on the Product Information Label.

Usage Notes: Recombinant RNasin® Ribonuclease Inhibitor is active over a broad pH range. Concentration gradients may form in frozen products and should be dispersed upon thawing. Mix well prior to use.

Table 1. Properties of Recombinant RNasin® Ribonuclease Inhibitor.

Property	Comment
Activity	Inactivates RNase by noncovalent binding
Molecular weight	49,847 daltons
Type of inhibition	Noncompetitive (3)
Isoelectric point	pI 4.7
pH activity range	pH 5.5–9 (4)
Binding ratio with RNase A	1:1 (3)
Constant for binding inhibition	$K_i = 4 \times 10^{-14}$M (3,4)
Amount to use	1 unit of inhibitor per microliter of solution
Reaction conditions to avoid	Temperatures >50°C, urea, SDS, other denaturants

Table 2. Effectiveness of Recombinant RNasin® Ribonuclease Inhibitor Against Selected Nucleases.

Inhibits	Does Not Inhibit
RNase A	RNase T1
RNase B	S1 Nuclease
RNase C	RNase from *Aspergillus sp.*
human placental RNase	RNase H, RNase ONE™ Ribonuclease, *Taq* DNA polymerase, ImProm-II™, AMV or M-MLV Reverse Transcriptase, SP6, T7 or T3 RNA polymerase

Quality Control Assays

Contaminant Activity

RNase Assays: To test for the presence of RNase activity, 1µg of RNA is incubated with 200 units of Recombinant RNasin® Ribonuclease Inhibitor for 1 hour at 37°C, and the RNA is then visualized on an ethidium bromide-stained agarose gel to verify the absence of degradation. To test for the presence of latent RNase activity, RNasin® Ribonuclease Inhibitor is heat-denatured at 67°C for 15 minutes and the equivalent of 200 units are then incubated with 1µg of RNA for 1 hour at 37°C. The RNA is then visualized on an ethidium bromide-stained agarose gel. No RNA degradation is detected.

DNase Assay: To test for DNase activity, 50ng of radiolabeled DNA is incubated with 200 units of Recombinant RNasin® Ribonuclease Inhibitor for 1 hour at 37°C, and the release of radiolabeled nucleotides is monitored by scintillation counting of TCA-soluble material. Minimum passing specification is <3% release.

Endonuclease Assay: To test for endonuclease activity, 1µg of supercoiled plasmid DNA is incubated with 200 units of Recombinant RNasin® Ribonuclease Inhibitor for 2 hours at 37°C in Promega Restriction Enzyme Buffer B (6mM Tris-HCl [pH 7.5], 50mM NaCl, 6mM $MgCl_2$, 1mM DTT). Following incubation, the supercoiled (Type I) DNA is visualized on an ethidium bromide-stained agarose gel to verify the absence of visible nicking or cutting.

Physical Purity: The purity is >90% as judged by SDS-polyacrylamide gels with Coomassie® blue staining.

Signed by:

C. Stollberg, Quality Assurance

AF9PIN251 0418N251

Promega

Promega Corporation

2800 Woods Hollow Road	
Madison, WI 53711-5399	USA
Telephone	608-274-4330
Toll Free	800-356-9526
Fax	608-277-2516
Internet	www.promega.com

PRODUCT USE LIMITATIONS, WARRANTY, DISCLAIMER

Promega manufactures products for a number of intended uses. Please refer to the product label for the intended use statements for specific products. Promega products contain chemicals which may be harmful if misused. Due care should be exercised with all Promega products to prevent direct human contact.

Each Promega product is shipped with documentation stating specifications and other technical information. Promega products are warranted to meet or exceed the stated specifications. Promega's sole obligation and the customer's sole remedy is limited to replacement of products free of charge in the event products fail to perform as warranted. Promega makes no other warranty of any kind whatsoever, and SPECIFICALLY DISCLAIMS AND EXCLUDES ALL OTHER WARRANTIES OF ANY KIND OR NATURE WHATSOEVER, DIRECTLY OR INDIRECTLY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, AS TO THE SUITABILITY, PRODUCTIVITY, DURABILITY, FITNESS FOR A PARTICULAR PURPOSE OR USE, MERCHANTABILITY, CONDITION, OR ANY OTHER MATTER WITH RESPECT TO PROMEGA PRODUCTS. In no event shall Promega be liable for claims for any other damages, whether direct, incidental, foreseeable, consequential, or special (including but not limited to loss of use, revenue or profit), whether based upon warranty, contract, tort (including negligence) or strict liability arising in connection with the sale or the failure of Promega products to perform in accordance with the stated specifications.

© 1996–1998, 2000–2002, 2005, 2008, 2013, 2015, 2016, 2018 Promega Corporation. All Rights Reserved.

Riboprobe, RNasin and TNT are registered trademarks of Promega Corporation. ImProm-II and RNase ONE are a trademarks of Promega Corporation.

Coomassie is a registered trademark of Imperial Chemical Industries, Ltd.

Products may be covered by pending or issued patents or may have certain limitations. Please visit our Web site for more information.

All specifications are subject to change without prior notice.

Product claims are subject to change. Please contact Promega Technical Services or access the Promega online catalog for the most up-to-date information on Promega products.

Part# 9PIN251

Printed in USA. Revised 4/18

Promega

Usage Information

1. Description

RNasin® Ribonuclease Inhibitors have broad-spectrum RNase inhibitory properties, including inhibition of eukaryotic RNases of the neutral type (1; see Table 1). The 50kDa protein exerts its inhibitory effect by noncovalently binding to RNases at a 1:1 ratio. The K_i value for the binding of RNasin® Ribonuclease Inhibitor to RNase (e.g., RNase A) is approximately 10^{-14}M (2–4). Typically, antibodies by comparison have a binding constant of 10^{-6}–10^{-9}M. In addition, the kinetics of association for RNasin® Ribonuclease Inhibitor is very rapid, ensuring immediate complexing and inhibition of RNase. Promega offers two different preparations: Natural RNasin® Ribonuclease Inhibitor and Recombinant RNasin® Ribonuclease Inhibitor. These products are purified using a combination of ion exchange and affinity chromatography. They are devoid of DNA exonuclease and endonuclease activity and RNase activity. In addition to its ability to inhibit RNase activity, RNasin® Ribonuclease Inhibitor has been shown to inhibit angiogenesis induced by angiogenin (5).

Recombinant RNasin® Ribonuclease Inhibitor offers the researcher an extra level of assurance of purity and consistency. Isolated from a recombinant *E. coli* strain, the N-terminus is an unblocked serine residue.

General Considerations: Since ribonucleases typically retain activity under denaturing conditions, care must be taken to avoid denaturing RNasin® Ribonuclease Inhibitor molecules that have complexed with ribonuclease. To prevent the release of active ribonuclease, temperatures greater than 50°C and high concentrations of urea or other denaturing agents should be avoided. RNasin® Ribonuclease Inhibitors are active over a broad pH range. If diluted and stored for extended periods of time, include DTT (minimum concentration 1mM).

2. Standard Applications

Both Recombinant and Natural RNasin® Ribonuclease Inhibitor can be used interchangeably in in vitro transcription and translation applications, described below.

For more information on systems and protocols for in vitro transcription, please request the *Riboprobe® In Vitro Transcription Systems Technical Manual* #TM016.

A. Transcription In Vitro (unlabeled RNA)

The standard in vitro transcription assay below uses RNasin® Ribonuclease Inhibitor at a final concentration of 1u/µl. With appropriate modifications, this reaction can be used for in vitro transcription analysis in a variety of experimental applications.

5X transcription buffer	20µl
DTT, 100mM	10µl
RNasin® Ribonuclease Inhibitor	100u
ATP, GTP, CTP and UTP, 2.5mM each*	20µl
linearized plasmid DNA, 2–5µg in water or TE buffer	2µl
RNA polymerase; SP6, T3 or T7	0–50u
Nuclease-free water to a final volume of	100µl

Incubate for 60–120 minutes at 37–40°C.

*Prepare by mixing equal volumes of four 10mM rNTP stocks.

B. Transcription In Vitro (^{32}P-labeled RNA probes)

5X transcription buffer	4µl
DTT, 100mM	2µl
RNasin® Ribonuclease Inhibitor	20u
ATP, GTP and UTP, 2.5mM each**	4µl
CTP, 100µM	2.4µl
Linearized template DNA, 0.2–1.0mg/ml in water or TE buffer	1µl
[α-^{32}P]CTP, 50µCi at 10mCi/ml	5µl
RNA polymerase; SP6, T3 or T7	1µl
Nuclease-free water to a final volume of	20µl

Incubate for 60 minutes at 37–40°C.

**Mix 1 volume of water with 1 volume each of 10mM ATP, GTP and UTP stock solutions.

C. Translation In Vitro

Include RNasin® Ribonuclease Inhibitor in standard and coupled in vitro translation systems to ensure protection of RNA substrates.

Sample Reaction using Rabbit Reticulocyte Lysate for In Vitro Translation:

Rabbit Reticulocyte Lysate	35µl
Nuclease-free water	7µl
RNasin® Ribonuclease Inhibitor	40u
Amino Acid Mixture Minus Methionine, 1mM	1µl
[^{35}S]methionine (1,200Ci/mmol) at 10mCi/ml	4µl
RNA template in water	2µg
Final volume of	50µl

Incubate for 60 minutes at 30°C.

Sample Reaction using the TNT® Reticulocyte Lysate or Wheat Germ Extract Systems for Coupled Transcription/Translation:

TNT® Rabbit Reticulocyte Lysate or Wheat Germ Extract	25µl
TNT® Reaction Buffer	2µl
TNT® T3, T7 or SP6 RNA Polymerase	1µl
Amino Acid Mixture Minus Methionine, 1mM	1µl
[^{35}S]methionine (1,000Ci/mmol) at 10mCi/ml	4µl
RNasin® Ribonuclease Inhibitor, 40u/µl	40u
DNA template	1µg
Nuclease-free water to a final volume of	50µl

Incubate for 60–120 minutes at 30°C.

3. Composition of Buffers and Solutions

5X transcription buffer

200mM	Tris-HCl (pH 7.5)
30mM	$MgCl_2$
10mM	spermidine
50mM	NaCl

1X TE buffer

10mM	Tris-HCl (pH 8.0)
1mM	EDTA

4. References

1. Blackburn, P. and Moore, S. (1982) In: *The Enzymes*, Vol. XV, Part B, Academic Press, New York.
2. Blackburn, P., Wilson, G. and Moore, S. (1977) Ribonuclease inhibitor from human placenta. Purification and properties. *J. Biol. Chem.* **252**, 5904–10.
3. Lee, F.S., Auld, D.S. and Vallee, B.L. (1989) Tryptophan fluorescence as a probe of placental ribonuclease inhibitor binding to angiogenin. *Biochemistry* **28**, 219–24.
4. Shultz, J. and Hurst, R. (2001) Characterization of RNasin® Ribonuclease Inhibitor. *Promega Notes* **77**, 8–11.
5. Shapiro, R. and Vallee, B.L. (1987) Human placental ribonuclease inhibitor abolishes both angiogenic and ribonucleolytic activities of angiogenin. *Proc. Natl. Acad. Sci. USA* **84**, 2238–41.

Part# 9PIN251
Printed in USA. Revised 4/18